MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Therapeutic effect of onabotulinumtoxinA (BoNT/A) in hemifacial spasm and trigeminal neuralgia post Ramsay Hunt Syndrome type II

R. López-Castellanos, R. López-Contreras (San Salvador, El Salvador)

Meeting: 2016 International Congress

Abstract Number: 1765

Keywords: Botulinum toxin: Clinical applications: other, Bruxism, Hemifacial spasm(HFS), Ramsay Hunt syndrome

Session Information

Date: Thursday, June 23, 2016

Session Title: Other

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To evaluate the therapeutic and preventive effect of OnabotulinumtoxinA (BoNT/A) in the treatment of hemifacial spasm, bruxism, and trigeminal neuralgia post Ramsay Hunt Syndrome.

Background: Ramsay Hunt Syndrome (RHS) type II, is a cranial polyneuropathy, refers to the association of unilateral peripheral facial nerve palsy and herpes zoster infection of the ear, is caused by re-activation of the varicella-zoster virus within the geniculate ganglion. There are few studies that report the beneficial effect of BoNT/A injections for the management of the exceptionally infrequent association of ipsilateral hemifacial spasm, bruxism and post-herpetic trigeminal neuralgia as chronic neurological complications post RHS.

Methods: We conducted open administration of BoNT/A and follow-up for 7 years in patients with chronic neurological complications post RHS. BoNT/A was injected either intradermal or submucosal into the painful areas and their trigger zones of trigeminal nerve. Changes in movement disorder and neuropathic pain were evaluated. Patients reported their medication use (analgesics and preventative treatment) and baseline measures were determined before and after (30, 90, 180 and 270 days) BoNT/A injections. Assessment by medical observation, video recordings and by patients’ subjective ranting and Visual Analog Scale (VAS).

Results: From 321 patients with hemifacial spasm, only 4 fulfilled inclusion criteria. We report 4 immunocompetent adults with concomitant unilateral hemifacial spasm and trigeminal neuralgia post RHS type II. One of them also had ipsilateral bruxism. Three patients had recurrent episodes of herpes zoster oticus. After BoNT/A treatment, patients had a significant reduction in pain and movement disorder during 3-7 months, without side effects and all patient stopped analgesics and neuromodulators during maximal therapeutic effect of BoNT/A (Table 1, Table 2).

Conclusions: Our findings suggest that BoNT/A injections in trigeminal nerve trigger points are an effective and safe therapy for some chronic complications post RHS type II, such as hemifacial spasm, bruxism and trigeminal neuralgia, even in the presence of ipsilateral facial weakness.

To cite this abstract in AMA style:

R. López-Castellanos, R. López-Contreras. Therapeutic effect of onabotulinumtoxinA (BoNT/A) in hemifacial spasm and trigeminal neuralgia post Ramsay Hunt Syndrome type II [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/therapeutic-effect-of-onabotulinumtoxina-bonta-in-hemifacial-spasm-and-trigeminal-neuralgia-post-ramsay-hunt-syndrome-type-ii/. Accessed May 25, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/therapeutic-effect-of-onabotulinumtoxina-bonta-in-hemifacial-spasm-and-trigeminal-neuralgia-post-ramsay-hunt-syndrome-type-ii/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley